iBio
Newark · Founded 2008
About iBio
iBio develops and offers product applications of its iBioLaunch™ and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. Advantages over other systems include: success with proteins difficult or impossible to produce with other methods; broadly applicable to biologics, including monoclonal antibodies, other therapeutic proteins and vaccines; enables rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more. Additional benefits include a practically unlimited surge capacity for remedial action against bioterrorism and pandemic disease; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production.
Company Facts
- Founded: 2008
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $135.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2026)
- Ticker: nasdaq:IBIO
- Website: ibioinc.com
- Phone: 302-355-0650
Industries & Categories
Biotechnology, Genetics, Robotics, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/ibio-98863 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.